A multi-Center, prospective study for maintenance of remission after discontinuation of adalimumab therapy in ulcerative colitis patients
Not Applicable
Recruiting
- Conditions
- ulcerative colitis
- Registration Number
- JPRN-UMIN000020840
- Lead Sponsor
- Fukuyama Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with serious infection (sepsis etc.) 2.Patients with active tuberculosis 3.Patients with a history of hypersensitivity to any of the ingredients of Humira 4.Patients with a current or past history of demyelinating diseases (multiple sclerosis, etc.) 5.Patients with congestive heart failure 6.Patients with pregnancy or desiring for pregnancy 7.Patients with history of colectomy 8.Patients without informed consent 9.Patients who are considered ineligible for this study by the principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rate of sustained remission after discontinuation of adalimumab therapy
- Secondary Outcome Measures
Name Time Method